The application of serum sialic acid test in glioma diagnosis / 中国医师进修杂志

ABSTRACT

Objective:To explore the clinical value of serum sialic acid (SA) for brain glioma diagnosis.Methods:Sixty patients with brain glioma and 60 normal persons (control group) in Deqing People's Hospital from January 2016 to September 2018 were collected, and all the brain glioma patients were divided into low grade group and high grade group according to the pathological grading. The serum SA levels of all the subjects were detected by photocolorimetric method, and the results were analyzed statistically.Results:The positive rate of SA in control group, low grade group and high grade group was 1.7%(1/60), 59.1%(13/22) and 81.6%(31/38), and there was significant difference ( χ2= 6.49, P<0.05). The positive rate in high grade group was higher than that in low grade group and control group, the positive rate in low grade group was higher than that in control group, and there was significant difference ( P<0.05). The level of SA in control group, low grade group and high grade group was 50.9(46.1-58.1), 55.6(48.2-60.9), 64.8(57.9-73.9) mg/L, and there was significant difference ( H= 15.56, P<0.05). The level of SA in high grade group was higher than that in low grade group and control group, the level of SA in low grade group was higher than that in control group, and there was significant difference ( P<0.05). After operation, the level of SA was decreased. At 6 months after operation, the level of SA in low grade group and high grade group was significantly lower than that before operation [low grade group 50.4 (48.0-59.1) mg/L vs. 55.6(48.2-60.9) mg/L; high grade group 60.1 (46.0-62.4) mg/L vs. 64.8(57.9-73.9) mg/L] ( P<0.05). At 6 months after operation, the level of SA in high grade group was significantly higher than that in control group [60.1 (46.0-62.4) mg/L vs. 50.9(46.1-58.1) mg/L](P<0.05), but in lower grade group, there was no significant difference [50.4 (48.0-59.1) mg/L vs. 50.9(46.1-58.1) mg/L]( P>0.05). Conclusions:Serum SA can be used in auxiliary diagnosis and prognosis evaluation for brain glioma.